Evidence map›Paper›PMID 41106895›Full record

ArticleJACC. Case reports2025

Immune Checkpoint Inhibitor Myocarditis Masquerading as Brugada Syndrome.

Aleksandr Talishinsky, Kinan Bachour, Charlie Lin, Patrick Zakka, Khalil Bassam, Leslie Bull, Edward Garon, Yuliya Krokhaleva, Peter Hanna, Eric H Yang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aleksandr TalishinskyDepartment of Medicine, University of California at Los Angeles (UCLA), Los Angeles, California, USA. Electronic address: atalishinsky@mednet.ucla.edu.
Kinan BachourDivision of Cardiology, Department of Medicine, UCLA, Los Angeles, California, USA.
Charlie LinDivision of Cardiology, Department of Medicine, UCLA, Los Angeles, California, USA.
Patrick ZakkaDivision of Cardiology, Department of Medicine, UCLA, Los Angeles, California, USA.
Khalil BassamDepartment of Medicine, University of California at San Francisco-Fresno, Fresno, California, USA.
Leslie BullDepartment of Medicine, University of California at Los Angeles (UCLA), Los Angeles, California, USA.
Edward GaronDivision of Hematology/Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA.
Yuliya KrokhalevaDivision of Cardiology, Department of Medicine, UCLA, Los Angeles, California, USA.
Peter HannaDivision of Cardiology, Department of Medicine, UCLA, Los Angeles, California, USA.
Eric H YangDivision of Cardiology, Department of Medicine, UCLA, Los Angeles, California, USA; UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, UCLA, Los Angeles, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitor (ICI)-associated myocarditis is a rare but severe complication of novel cancer immunotherapies. Here, we present the first known case of Brugada electrocardiographic (ECG) phenocopy in the setting of ICI-associated myocarditis. CASE SUMMARY: A 67-year-old man presented with chest pain and syncope 5 weeks after his first dose of pembrolizumab for lung adenocarcinoma. Troponin biomarkers were elevated, cardiac magnetic resonance was consistent with myocarditis, and serial electrocardiograms showed dynamic ST-segment changes with intermittent type 2 Brugada pattern. Coronary angiography revealed nonobstructive coronary artery disease. His myocarditis and Brugada pattern resolved with prompt treatment. Further electrophysiology and genetic testing were negative for Brugada syndrome. DISCUSSION: This case highlights the importance of early diagnosis and treatment of ICI-associated myocarditis, and the need for further research to elucidate the mechanisms, risk factors, and prognostic significance of associated ECG changes. We discuss management strategies for Brugada phenocopy in ICI-associated myocarditis and implications for cardio-oncology and electrophysiology practice. TAKE-HOME MESSAGES: ICI-associated myocarditis can present with type 2 Brugada ECG phenocopy. Early diagnosis and guideline-directed treatment of ICI-associated myocarditis are essential.

Indexed as

cancerchest painelectrocardiogramelectrophysiologyphenotype

Identifiers

PMID41106895
PMCPMC12793847

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.